Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Shares Gap Down – Here’s What Happened

Greenland Mines Ltd. Common Stock (NASDAQ:GRML)’s share price gapped down prior to trading on Monday . The stock had previously closed at $10.1350, but opened at $9.43. Greenland Mines Ltd. Common Stock shares last traded at $8.56, with a volume of 41,940 shares trading hands.

More Greenland Mines Ltd. Common Stock News

Here are the key news stories impacting Greenland Mines Ltd. Common Stock this week:

• Positive Sentiment: CFO Jeff Leblanc purchased 14,000 GRML shares for approximately $136,080, increasing his ownership by 14.52%. The insider buying may signal confidence in Greenland Mines’ prospects. SEC insider transaction filing
• Positive Sentiment: A preliminary economic study valued the Sarfartoq Nd-Pr rare-earth project at up to $2.05 billion and estimated a 118.6% pretax internal rate of return. The study covers only the ST1 deposit, leaving potential for further resource growth. Sarfartoq economic study
• Positive Sentiment: An independent S-K 1300 resource estimate identified a high-grade Sarfartoq resource containing valuable magnet rare earths, including neodymium, praseodymium, dysprosium and terbium. The company said contained Nd-Pr oxide is equivalent to roughly five years of non-Chinese refined production in 2025. Sarfartoq mineral resource estimate
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. The data do not indicate meaningful short-selling pressure, although the reported percentage change was unavailable.
• Neutral Sentiment: Trading was temporarily halted for pending news, increasing volatility and attention around the company’s announcements.
• Negative Sentiment: Greenland Mines announced a proposed public offering of common stock or common-stock equivalents. Because the company has not disclosed the offering size, pricing or terms, investors face uncertainty and potential share dilution. Greenland Mines proposed public offering
• Negative Sentiment: The recently announced 1-for-50 reverse split may improve the trading price and exchange compliance, but it does not change the company’s underlying value and can heighten volatility or signal financing pressure.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GRML shares. Wall Street Zen upgraded Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings downgraded Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Greenland Mines Ltd. Common Stock Stock Performance

The company has a market capitalization of $30.88 million, a PE ratio of -30.34 and a beta of 7.13. The stock’s fifty day simple moving average is $10.86 and its 200-day simple moving average is $17.56.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last issued its quarterly earnings results on Monday, August 17th. The company reported ($1.50) earnings per share for the quarter.

Insider Buying and Selling at Greenland Mines Ltd. Common Stock

In other Greenland Mines Ltd. Common Stock news, CFO Jeff Leblanc bought 14,000 shares of Greenland Mines Ltd. Common Stock stock in a transaction that occurred on Tuesday, August 25th. The shares were acquired at an average price of $9.72 per share, for a total transaction of $136,080.00. Following the acquisition, the chief financial officer owned 110,406 shares of the company’s stock, valued at $1,073,146.32. The trade was a 14.52% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Riad Hussein El-Dada sold 3,500 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.50, for a total value of $40,250.00. Following the completion of the sale, the director owned 3,500 shares of the company’s stock, valued at approximately $40,250. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 11.30% of the stock is owned by company insiders.

Institutional Trading of Greenland Mines Ltd. Common Stock

A number of hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in Greenland Mines Ltd. Common Stock in the second quarter worth about $26,000. XTX Topco Ltd grew its position in Greenland Mines Ltd. Common Stock by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after purchasing an additional 80,768 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Greenland Mines Ltd. Common Stock in the 4th quarter valued at approximately $126,000. Geode Capital Management LLC increased its holdings in shares of Greenland Mines Ltd. Common Stock by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after purchasing an additional 167,905 shares during the period. Finally, Brummer Multi Strategy AB acquired a new position in Greenland Mines Ltd. Common Stock during the 4th quarter valued at about $175,000. Institutional investors and hedge funds own 20.07% of the company’s stock.

About Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.